Surrozen Q2 net income $50.2 million, driven by $59.6 million in non-cash gains
Surrozen reported second quarter 2026 revenue of $5.0 million, up from $983,000 a year earlier, from a Boehringer Ingelheim milestone. Net income rose to $50.2 million, but the company said it was driven by $59.6 million in non-cash gains on fair value changes, while its operating loss widened to $10.4 million. Diluted earnings per share were $(0.41), compared with $2.55 a year earlier, and cash fell to $102.0 million from $106.9 million at March 31, 2026.
Key points
- Q2 2026 collaboration and license revenue was $5.0 million from a June 2026 Boehringer Ingelheim milestone; prior-year research service revenue was $983,000.
- Loss from operations was $10.4 million versus $9.0 million a year earlier, as R&D rose to $8.5 million and G&A to $6.9 million.
- Diluted EPS was $(0.41) versus $2.55 a year earlier, while the six-month net loss was $77.3 million compared with net income of $12.8 million in the prior-year period.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.